Effect of a Simple Dose-Escalation Schedule on Tramadol Tolerability: Assessment in the Clinical Setting

Authors: I. Tagarro1; J. Herrera2; C. Barutell3; M.C. Díez1; M. Marín4; D. Samper5; C. Busquet6; M.J. Rodríguez7

Source: Clinical Drug Investigation, Volume 25, Number 1, 2005 , pp. 23-31(9)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: To assess the effect of a very simple dose-escalation schedule on tramadol tolerability in clinical practice. This schedule consists of starting treatment with sustained-release tramadol 50mg twice daily, and escalating the dose around 7 days later to 100mg twice daily.

Methods: Data from 1925 outpatients with non-malignant chronic pain were collected in this multicentre, prospective, comparative, non-randomised, open, observational study.

Results: A total of 1071 patients (55.6%) were included in the dose-escalation group (50mg group) and 854 patients (44.4%) in the control group (sustained-release tramadol 100mg twice daily; 100mg group). The proportion of patients who interrupted tramadol treatment due to the occurrence of adverse reactions was significantly lower in the 50mg group (5.6%) than in the 100mg group (12.6%) [p = 0.001]. In line with this, the proportion of patients who experienced at least one adverse reaction was significantly lower in the 50mg group (18.4%) than in the 100mg group (30.4%) [p = 0.001] and, interestingly, the two most frequently reported adverse reactions, nausea and dizziness, were found with a significantly lower frequency in the 50mg group (p < 0.001). Multivariate analysis showed that the risk of safety-related treatment cessations was 2.3 times higher in the 100mg group than in the 50mg group, and 2.2 times higher in females than in males. The two treatments were equally effective in reducing pain intensity (p = 0.121), measured as a reduction in pain score obtained by means of a visual analogue scale.

Conclusion: The instauration of tramadol treatment, starting with sustained-release 50mg capsules twice daily and escalating the dose some days later to 100mg twice daily, was shown to be an effective and easy way to improve tramadol tolerability in clinical practice, whilst maintaining its analgesic efficacy.

Document Type: Research article

Affiliations: 1: 1 Viatris Pharmaceuticals SA, Madrid, Spain 2: 2 Hospital de Valme, Sevilla, Spain 3: 3 Hospital Vall d’Hebron, Barcelona, Spain 4: 4 Hospital San Juan de Dios, San Sebastián, Spain 5: 5 Hospital Germans Trias i Pujol, Barcelona, Spain 6: 6 Hospital Dr. Josep Trueta, Girona, Spain 7: 7 Hospital Civil de Málaga, Málaga, Spain

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$62.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A